Cargando…
A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors
A critical requirement in neuroendocrine tumor (NET) management is a blood biomarker test that is sensitive, specific and reproducible. We evaluated a PCR-based 51-transcript signature to detect tumors, compared it with chromogranin A (CgA) and examined the confounding effect of proton pump inhibito...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473957/ https://www.ncbi.nlm.nih.gov/pubmed/25316294 http://dx.doi.org/10.1530/EC-14-0100 |
_version_ | 1784575112930918400 |
---|---|
author | Modlin, Irvin M Aslanian, Harry Bodei, Lisa Drozdov, Ignat Kidd, Mark |
author_facet | Modlin, Irvin M Aslanian, Harry Bodei, Lisa Drozdov, Ignat Kidd, Mark |
author_sort | Modlin, Irvin M |
collection | PubMed |
description | A critical requirement in neuroendocrine tumor (NET) management is a blood biomarker test that is sensitive, specific and reproducible. We evaluated a PCR-based 51-transcript signature to detect tumors, compared it with chromogranin A (CgA) and examined the confounding effect of proton pump inhibitors (PPIs), which cause falsely elevated CgA levels. The multigene signature was evaluated in two groups. Group 1: 125 prospectively collected NETs: gastroenteropancreatic NETs (n=91, including 42 pancreatic and 40 small intestinal), carcinoids of unknown primary (n=18) and other sites (n=16). Group 2: prospectively collected non-NET patients receiving PPIs (>1 month; dyspepsia, n=19; GERD, n=6; and pancreatitis, n=4) and 50 controls. All samples were analyzed by PCR (marker genes) and ELISA (DAKO–CgA). Sensitivity comparisons included χ (2), non-parametric measurements, and receiver operating characteristic (ROC) curves. Group 1: 123 NETs were PCR-positive (98.4%) compared with 50 (40%) CgA-positive (χ (2)=97.3, P<10(−26)). Significant differences (P<0.001) were noted between pancreas: PCR 95% vs CgA 29.2% (P<10(−9)) and small intestine: 100 vs 58% (P<10(−4)). The multigene test was elevated in all grades (G1–G3), in both local and disseminated disease, and was not normalized by somatostatin analog therapy. It was also elevated in 97% of CgA normal NETs. Group 2: PPI administration increased CgA in 83% and CgA was elevated in 26% of controls. PCR values were not elevated in either group. PCR performance metrics were as follows: sensitivity 98.4%, specificity 100%, positive predictive value 100%, negative predictive value 97.8%, and the ROC-derived area under the curve (AUC) was 0.997. These were significantly better than CgA (all metrics <60%; AUC, 0.54; Z-statistic, 10.44, P<0.0001). A 51-panel multigene blood transcript analysis is significantly more sensitive than plasma CgA for NET detection and is unaffected by acid suppression therapy. |
format | Online Article Text |
id | pubmed-8473957 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Bioscientifica Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-84739572021-10-01 A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors Modlin, Irvin M Aslanian, Harry Bodei, Lisa Drozdov, Ignat Kidd, Mark Endocr Connect Research A critical requirement in neuroendocrine tumor (NET) management is a blood biomarker test that is sensitive, specific and reproducible. We evaluated a PCR-based 51-transcript signature to detect tumors, compared it with chromogranin A (CgA) and examined the confounding effect of proton pump inhibitors (PPIs), which cause falsely elevated CgA levels. The multigene signature was evaluated in two groups. Group 1: 125 prospectively collected NETs: gastroenteropancreatic NETs (n=91, including 42 pancreatic and 40 small intestinal), carcinoids of unknown primary (n=18) and other sites (n=16). Group 2: prospectively collected non-NET patients receiving PPIs (>1 month; dyspepsia, n=19; GERD, n=6; and pancreatitis, n=4) and 50 controls. All samples were analyzed by PCR (marker genes) and ELISA (DAKO–CgA). Sensitivity comparisons included χ (2), non-parametric measurements, and receiver operating characteristic (ROC) curves. Group 1: 123 NETs were PCR-positive (98.4%) compared with 50 (40%) CgA-positive (χ (2)=97.3, P<10(−26)). Significant differences (P<0.001) were noted between pancreas: PCR 95% vs CgA 29.2% (P<10(−9)) and small intestine: 100 vs 58% (P<10(−4)). The multigene test was elevated in all grades (G1–G3), in both local and disseminated disease, and was not normalized by somatostatin analog therapy. It was also elevated in 97% of CgA normal NETs. Group 2: PPI administration increased CgA in 83% and CgA was elevated in 26% of controls. PCR values were not elevated in either group. PCR performance metrics were as follows: sensitivity 98.4%, specificity 100%, positive predictive value 100%, negative predictive value 97.8%, and the ROC-derived area under the curve (AUC) was 0.997. These were significantly better than CgA (all metrics <60%; AUC, 0.54; Z-statistic, 10.44, P<0.0001). A 51-panel multigene blood transcript analysis is significantly more sensitive than plasma CgA for NET detection and is unaffected by acid suppression therapy. Bioscientifica Ltd 2014-10-14 /pmc/articles/PMC8473957/ /pubmed/25316294 http://dx.doi.org/10.1530/EC-14-0100 Text en © 2014 The authors https://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Modlin, Irvin M Aslanian, Harry Bodei, Lisa Drozdov, Ignat Kidd, Mark A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors |
title | A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors |
title_full | A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors |
title_fullStr | A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors |
title_full_unstemmed | A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors |
title_short | A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors |
title_sort | pcr blood test outperforms chromogranin a in carcinoid detection and is unaffected by proton pump inhibitors |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473957/ https://www.ncbi.nlm.nih.gov/pubmed/25316294 http://dx.doi.org/10.1530/EC-14-0100 |
work_keys_str_mv | AT modlinirvinm apcrbloodtestoutperformschromograninaincarcinoiddetectionandisunaffectedbyprotonpumpinhibitors AT aslanianharry apcrbloodtestoutperformschromograninaincarcinoiddetectionandisunaffectedbyprotonpumpinhibitors AT bodeilisa apcrbloodtestoutperformschromograninaincarcinoiddetectionandisunaffectedbyprotonpumpinhibitors AT drozdovignat apcrbloodtestoutperformschromograninaincarcinoiddetectionandisunaffectedbyprotonpumpinhibitors AT kiddmark apcrbloodtestoutperformschromograninaincarcinoiddetectionandisunaffectedbyprotonpumpinhibitors AT modlinirvinm pcrbloodtestoutperformschromograninaincarcinoiddetectionandisunaffectedbyprotonpumpinhibitors AT aslanianharry pcrbloodtestoutperformschromograninaincarcinoiddetectionandisunaffectedbyprotonpumpinhibitors AT bodeilisa pcrbloodtestoutperformschromograninaincarcinoiddetectionandisunaffectedbyprotonpumpinhibitors AT drozdovignat pcrbloodtestoutperformschromograninaincarcinoiddetectionandisunaffectedbyprotonpumpinhibitors AT kiddmark pcrbloodtestoutperformschromograninaincarcinoiddetectionandisunaffectedbyprotonpumpinhibitors |